Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Recursion Pharmaceuticals (RXRX)
NASDAQ:RXRX
RESEARCH TOOLSreports
Recursion Pharmaceuticals (RXRX) Stock Price & Analysis
1,212 Followers
RXRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.97 - $16.75
Previous Close$9.42
Volume4.74M
Average Volume (3M)6.21M
Market Cap
$2.24B
Enterprise Value$1.90B
Total Cash (Recent Filing)$387.32M
Total Debt (Recent Filing)$51.48M
Price to Earnings (P/E)-5.9
Beta2.34
Next Earnings
Aug 06, 2024EPS Estimate
-$0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.60
Shares Outstanding237,663,668
10 Day Avg. Volume6,149,717
30 Day Avg. Volume6,212,700
Standard Deviation0.30
R-Squared0.02
Alpha-0.00739
Financial Highlights & Ratios
Price to Book (P/B)5.97
Price to Sales (P/S)54.44
Price to Cash Flow (P/CF)-7.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue40.15
Enterprise Value/Gross Profit-225.52
Enterprise Value/Ebitda-9.51
Forecast
1Y Price Target
$13.50Price Target Upside43.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Recursion Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trials ProgressPhase 2 data for REC-994 in cerebral cavernous malformation are expected, showing progress in the company's pipeline.
Financial StabilityThe company ended the fiscal year with a healthy cash position, providing financial stability for ongoing and future clinical trials.
Platform EnhancementCompany's computing power has been significantly upgraded with the launch of BioHive-2, improving its operational capabilities.
Bears Say
Financial HealthInvestor attention on the company's balance sheet is growing due to continued operational expenditure growth.
Research And DevelopmentR&D expenses were slightly below expectations, which could indicate a slower pace in research development compared to forecasts.
Revenue PerformanceRXRX missed Q4 revenues due to Roche/Genentech workflow timing.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
RXRX FAQ
What was Recursion Pharmaceuticals’s price range in the past 12 months?
Recursion Pharmaceuticals lowest stock price was $4.97 and its highest was $16.75 in the past 12 months.
What is Recursion Pharmaceuticals’s market cap?
Currently, no data Available
When is Recursion Pharmaceuticals’s upcoming earnings report date?
Recursion Pharmaceuticals’s upcoming earnings report date is Aug 06, 2024 which is in 78 days.
How were Recursion Pharmaceuticals’s earnings last quarter?
Recursion Pharmaceuticals released its earnings results on May 09, 2024. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.423 by $0.033.
Is Recursion Pharmaceuticals overvalued?
According to Wall Street analysts Recursion Pharmaceuticals’s price is currently Undervalued.
Does Recursion Pharmaceuticals pay dividends?
Recursion Pharmaceuticals does not currently pay dividends.
What is Recursion Pharmaceuticals’s EPS estimate?
Recursion Pharmaceuticals’s EPS estimate is -$0.41.
How many shares outstanding does Recursion Pharmaceuticals have?
Recursion Pharmaceuticals has 230,107,330 shares outstanding.
What happened to Recursion Pharmaceuticals’s price movement after its last earnings report?
Recursion Pharmaceuticals reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.423. Following the earnings report the stock price went down -0.463%.
Which hedge fund is a major shareholder of Recursion Pharmaceuticals?
Among the largest hedge funds holding Recursion Pharmaceuticals’s share is ARK Investment Management LLC. It holds Recursion Pharmaceuticals’s shares valued at 204M.
---
Recursion Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.50 (43.31% Upside)
$13.50 (43.31% Upside)
Blogger Sentiment
Bullish
RXRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 13.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.2%
Last 30 Days ▲ 6.6%
Last 30 Days ▲ 6.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
75.09%
12-Months-Change
Fundamentals
Return on Equity
-85.19%
Trailing 12-Months
Asset Growth
-11.08%
Trailing 12-Months
Company Description
Recursion Pharmaceuticals
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
---
RXRX Earnings Call
Q1 2024
0:00 / 0:00
---
RXRX Stock 12 Month Forecast
Average Price Target
$13.50
▲(43.31% Upside)
Technical Analysis
Sarepta Therapeutics
―
Alnylam Pharma
―
Arrowhead Pharmaceuticals
―
Vertex Pharmaceuticals
―
Best Analysts Covering RXRX
1 Year
---